Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28 September - 1 October
Safety Classified by Officially
At its monthly meeting, EMA’s safety committee (PRAC) carried out its broad range of responsibilities to manage the safety of medicines, including the assessment of safety signals, risk management plans, periodic safety update reports and post-authorisation safety studies.
The Committee did not start or conclude any referral procedures. Information on ongoing safety referrals is provided in the ‘Ongoing referrals’ table below.
Information on all topics discussed by the PRAC is available in the agenda.
Agenda of the PRAC meeting 28 September - 1 October 2026
Monthly figures for PRAC outcomes based on the draft agenda.
This is an extract. The publication continues at the source.
Source: European Medicines Agency.
Read the original at the source: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-28-september-1-october
Officially imported this from European Medicines Agency’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.
This publication has changed since it was first published
2 versions recorded. The original is kept in full — nothing is overwritten.
- v2 imported change on current
- v1 as first published on
Provenance
- Organization
- European Medicines Agency — imported from official source
- Official source
- https://www.ema.europa.eu/en/news.xml RSS
- Imported
- October 03, 2026 20:30
- Versions
- 2 recorded
- Identity
-
https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-...